Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis

NCT02429882 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02429882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2015
Completion date
May 31, 2015
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis